Genmab Announces Financial Results for the First Quarter of 2024

About this update from Genmab A/s

[{"type":"image","alt":"Genmab A/S","displaySize":"","headline":null,"caption":"Genmab A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":275,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3fXMaEmkURmdIw8oGLJV.g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0cd563151331363bc069dc3ced1531d","width":275,"height":85}},"lazy":false},{"type":"text","content":"May 8, 2025 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2025","length":91,"tagName":"p"},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"EPKINLY® (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL)","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Rinatabart sesutecan (Rina-S®) continues to show encouraging antitumor activity in patients with advanced ovarian cancer in data presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer® (SGO) ","length":222,"tagName":"p"}]},{"val":[{"type":"text","content":"Tivdak® (tisotumab vedotin) approved by the Japan MHLW and by the European Commission (EC) as the first and only antibody-drug conjugate (ADC) approved in both Japan and the European Union (EU) for the treatment of recurrent or metastatic cervical cancer after prior therapy","length":274,"tagName":"p"}]},{"val":[{"type":"text","content":"Genmab revenue increased 19% compared to the first quarter of 2024, to $715 million","length":83,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":762,"olType":false},{"type":"text","content":"“Our commitment to advancing our late-stage programs was reflected in the progress we made in the first quarter of the year. Both EPKINLY and Tivdak expanded their reach with approvals in additional territories and the updated Rina-S data presented at SGO reinforces its potential as a treatment option for patients with advanced ovarian cancer,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.","length":412,"tagName":"p"},{"type":"text","content":"Financial Performance First Quarter of 2025","length":43,"tagName":...

More updates from Genmab A/s